Therefore, strategies to mitigate the immunosuppressive milieu and revitalize T-cell activation, including by modulating CD8+CD28- T cell pathways, could significantly enhance immunotherapy efficacy in GBM patients. The gene discussed is CD28; the disease is glioblastoma.